**Supplemental Figure 1.** Error propagation of K_D to outcome measure of calculated SUVR for healthy (A) and AD (B) conditions for ^{11}C-PIB, ^{11}C-BF-227, ^{11}C-AZD2184, ^{11}C-SB-13, ^{18}F-FACT, ^{18}F-florbetapir, ^{18}F-florbetaben, ^{18}F-flutemetamol, ^{18}F-FDDNP, and ^{18}F-AZD4694. Each K_D for these 10 radioligands was varied by -20%, -16%,-12%, -8%, -4%, 0%, 4%, 8%, 12%, 16%, and 20% against original K_D in Table 2. Percentage difference from original SUVR is shown in these graphs.

Supplemental Figure 2. Predicted time-activity curves for the 10 amyloid radioligands in both target (healthy and AD) and reference regions. (A) ^{11}C-PIB, (B) ^{11}C-BF-227, (C) ^{11}C-AZD2184, (D) ^{11}C-SB-13, (E) ^{18}F-FACT, (F) ^{18}F-florbetapir, (G) ^{18}F-florbetaben, (H) ^{18}F-flutemetamol, (I) ^{18}F-FDDNP, and (J) ^{18}F-AZD4694. HC = healthy control.